The Motley Fool··Reuben Gregg BrewerRegencell's 21,000% Surge Masks Fundamental Risks in Unproven Biotech
Regencell Bioscience surged 21,000% despite zero revenue and no approved products, exemplifying speculative excess that investors should avoid.
PFERGCpenny stockdrug development